Advertisement

Topics

PubMed Journals Articles About "Ranibizumab For The Treatment Of Choroidal Neovascularisation (CNV) Secondary To Pathological Myopia (PM): An Individualized Regimen" RSS

00:58 EST 19th January 2019 | BioPortfolio

Ranibizumab For The Treatment Of Choroidal Neovascularisation (CNV) Secondary To Pathological Myopia (PM): An Individualized Regimen PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Ranibizumab For The Treatment Of Choroidal Neovascularisation (CNV) Secondary To Pathological Myopia (PM): An Individualized Regimen articles that have been published worldwide.

More Information about "Ranibizumab For The Treatment Of Choroidal Neovascularisation (CNV) Secondary To Pathological Myopia (PM): An Individualized Regimen" on BioPortfolio

We have published hundreds of Ranibizumab For The Treatment Of Choroidal Neovascularisation (CNV) Secondary To Pathological Myopia (PM): An Individualized Regimen news stories on BioPortfolio along with dozens of Ranibizumab For The Treatment Of Choroidal Neovascularisation (CNV) Secondary To Pathological Myopia (PM): An Individualized Regimen Clinical Trials and PubMed Articles about Ranibizumab For The Treatment Of Choroidal Neovascularisation (CNV) Secondary To Pathological Myopia (PM): An Individualized Regimen for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Ranibizumab For The Treatment Of Choroidal Neovascularisation (CNV) Secondary To Pathological Myopia (PM): An Individualized Regimen Companies in our database. You can also find out about relevant Ranibizumab For The Treatment Of Choroidal Neovascularisation (CNV) Secondary To Pathological Myopia (PM): An Individualized Regimen Drugs and Medications on this site too.

Showing "Ranibizumab Treatment Choroidal Neovascularisation Secondary Pathological Myopia Individualized" PubMed Articles 1–25 of 33,000+

Fluorescein Leakage and Optical Coherence Tomography Features of Choroidal Neovascularization Secondary to Pathologic Myopia.

We compare the fluorescein angiography (FA) patterns with morphologic alterations detectable on spectral-domain OCT (SD-OCT) in myopic choroidal neovascularization (mCNV) and evaluate whether they influence the effects of intravitreal ranibizumab (IVRI) in an as-needed (PRN) regimen.


Long-term results of photodynamic therapy or ranibizumab for polypoidal choroidal vasculopathy in LAPTOP study.

We previously reported that ranibizumab performed better on visual prognosis than photodynamic therapy (PDT) in a Ranibizumab (ucentis) nd hotodynamic herapy n olypoidal choroidal vasculopathy (LAPTOP) study. To determine if the first-choice treatment, either PDT or intravitreal ranibizumab, has a long-term effect in patients with polypoidal choroidal vasculopathy (PCV).

Imaging in myopia: potential biomarkers, current challenges and future developments.

Myopia is rapidly increasing in Asia and around the world, while it is recognised that complications from high myopia may cause significant visual impairment. Thus, imaging the myopic eye is important for the diagnosis of sight-threatening complications, monitoring of disease progression and evaluation of treatments. For example, recent advances in high-resolution imaging using optical coherence tomography may delineate early myopic macula pathology, optical coherence tomography angiography may aid early ch...


Effects of posterior scleral reinforcement in pathological myopia: a 3-year follow-up study.

To assess the effects of posterior sclera reinforcement (PSR) in refractive outcomes, choroidal thickness (CT), and retinal thickness (RT) during a 3-year follow-up in eyes with pathological myopia.

Design and Baseline Characteristics of the HELP Study: An Extended and Long-Term Observation of Pathological Myopia in Caucasians.

To assess the natural disease progression of high myopia in Caucasians considered at risk for the development of myopic choroidal neovascularization (mCNV).

RANIBIZUMAB VERSUS VERTEPORFIN PHOTODYNAMIC THERAPY IN ASIAN PATIENTS WITH MYOPIC CHOROIDAL NEOVASCULARIZATION: BRILLIANCE, a 12-Month, Randomized, Double-Masked Study.

To evaluate the efficacy and safety of 2 dosing regimens of ranibizumab 0.5 mg versus verteporfin photodynamic therapy in Asian patients with visual impairment due to myopic choroidal neovascularization.

Progress and Control of Myopia by Light Environments.

During the past 30 years, the prevalence rate of myopia has been increased dramatically. Myopia has become one of the leading causes of vision loss in some countries, whereas the mechanism of the main pathological change in myopia is still largely unknown. Although several studies showed genetic background influences the phenotype of myopia to some extent, the sudden increase of morbidity cannot be explained by genetics only. The change in lifestyle results in tremendous change in the light environment, whi...

Durability of Diabetic Retinopathy Improvement with As-Needed Ranibizumab: Open-label Extension of RIDE and RISE Studies.

To evaluate durability of diabetic retinopathy (DR) improvements after a change in ranibizumab dosing from monthly to individualized pro re nata (PRN) therapy.

MULTIMODAL IMAGING OF FOCAL CHOROIDAL EXCAVATION COMPLICATED BY CHOROIDAL NEOVASCULARIZATION IN A PATIENT WITH ANGIOID STREAKS AND PSEUDOXANTHOMA ELASTICUM.

To describe a case of focal choroidal excavation (FCE) complicated with Type-2 choroidal neovascularization (CNV) in a patient with angioid streaks secondary to pseudoxanthoma elasticum before and after treatment with bevacizumab.

Tessellated fundus appearance and its association with myopic refractive error.

The appearance of tessellated fundus in an eye may act as a marker in identifying visual performance, degree of myopia or risk of progression of myopia in a given eye. A systematic literature search using key words was performed using PubMed, Web of Science and Google Scholar and of the 832 studies identified, 10 full-length articles, which met the inclusion criteria, were considered for review. The primary outcome measures were association of tessellated fundus with: (i) visual acuity, (ii) refractive erro...

Choroidal thickness changes in non-treated acute and ranibizumab-treated chronic central serous chorioretinopathy.

To evaluate the changes in subfoveal retinal, and choroidal thicknesses (CT) in the non-treated acute and the ranibizumab-treated chronic central serous chorioretinopathy (CSCR) patients.This retrospective study included 32 eyes of 32 consecutive patients with CSCR. There were 12 patients who presented with a spontaneous resolution of CSCR (Group 1) and 20 patients who were treated with ranibizumab for persistent subretinal fluid (SRF) (Group 2). Optical coherence tomography (OCT) imaging of subfoveal retin...

Myopia: is the nature-nurture debate finally over?

In the nineteenth century, the prevalence of myopia began to rise, and Cohn stressed the role of education. Later, based on twin studies, Sorsby argued that refraction was almost totally genetically determined. This became the dominant view. However, rapid increases in the prevalence of myopia were then reported, especially in East and Southeast Asia, where the prevalence of myopia in children completing secondary school is now 80-90 per cent, with around 20 per cent highly myopic, and at risk of ocular...

RANIBIZUMAB IN PIGMENT EPITHELIAL TEARS SECONDARY TO AGE-RELATED MACULAR DEGENERATION: A Prospective Study.

To assess efficacy of intravitreal ranibizumab in retinal pigment epithelium tears secondary to neovascular age-related macular degeneration.

Factors predicting 2-year treatment results of ranibizumab therapy for polypoidal choroidal vasculopathy in eyes with good baseline visual acuity.

This study aimed to explore predictors of long-term stabilization of polypoidal choroidal vasculopathy (PCV) lesions and vision in response to injection of intravitreal ranibizumab (IVR). The treated eyes had a baseline best corrected visual acuity (BCVA) of at least 0.6 (logarithm of the minimal angle of resolution (logMAR) 0.22).We treated 45 eyes showing BCVA between 0.6 (logMAR 0.22) and 1.0 (logMAR 0), with IVR for 3 consecutive months. All eyes were confirmed to have subfoveal PCV prior to starting th...

3-year-data of combined navigated laser photocoagulation (Navilas) and intravitreal ranibizumab compared to ranibizumab monotherapy in DME patients.

The prospective, comparative evaluation of combined navigated laser photocoagulation and intravitreal ranibizumab in the treatment of diabetic macular edema has shown advantage of a combination therapy compared to ranibizumab monotherapy at year 1 with significantly reduced injections. The purpose of this retrospective study was to determine the long-term visual gains and need of injections in a 3 year-follow-up period.

Monthly Versus Treat-and-Extend Ranibizumab for Diabetic Macular Edema: A Prospective, Randomized Trial.

Compare fixed monthly dosing of ranibizumab to treat-and-extend (T&E) ranibizumab during a period of 24 months for diabetic macular edema (DME) treatment.

Prognostic Tomographic Classification of Myopic Choroidal Neovascularization.

To investigate the prognostic value of the development of a hyperreflective envelopment of the neovascular tissue in myopic choroidal neovascularization (mCNV) after the first intravitreal ranibizumab injection and to establish a tomographic classification of mCNV depending on this healing process.

Hyperreflective Foci Number Correlates with Choroidal Neovascularization Activity in Angioid Streaks.

To assess the changes in hyperreflective foci (HF) by means of spectral-domain optical coherence tomography (SD-OCT) in patients undergoing anti-VEGF treatment for subfoveal choroidal neovascularization (CNV) secondary to angioid streaks (AS).

Myopia and orthokeratology for myopia control.

The prevalence of myopia in children is increasing worldwide and is viewed as a major public health concern. This increase has driven interest in research into myopia prevention and control in children. Although there is still uncertainty in the risk factors underlying differences in myopia prevalence between ethnic groups, rates in children of East Asian descent are typically higher regardless of where they live. Mounting evidence also suggests that myopia prevalence in children increases with age. Earlier...

Establishment of an induced pluripotent stem cell line (FDEENTi001-A) from a patient with pathological myopia.

Pathological myopia (PM) is a retinal degenerative disease with an increasing prevalence in Asia. The peripheral blood mononuclear cells (PBMCs) from a patient with PM were successfully reprogrammed to induced pluripotent stem cells (iPSCs) using integration-free method, Sendai viral (SeV) vectors expressing OCT4, SOX2, KLF4 and C-MYC. This line may provide a useful resource for exploring the pathogenesis of PM.

PSEUDOXANTHOMA ELASTICUM: SUCCESSFUL LONG-TERM MANAGEMENT OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO ANGIOID STREAKS WITH PRO RE NATA INTRAVITREAL BEVACIZUMAB INJECTIONS.

To demonstrate how a patient with recurrent episodes of choroidal neovascularization (CNV), secondary to angioid streaks, can be managed successfully with a pro re nata regime of intravitreal bevacizumab injection over an eight-year period.

Glaucoma treatment in high myopia.

Both high myopia and glaucoma can have devastating effects on the visual function. Diagnostic tests and treatment can be challenging when both diseases are coexistent. This article discusses some of the typical problems in the management of glaucoma in highly myopic patients.

Controlling Progression of Myopia: Optical and Pharmaceutical Strategies.

The burden associated with the rising prevalence of myopia and high myopia, and the associated vision impairment and sight-threatening complications, has triggered the need to evaluate strategies to control the progression of myopia. We provide an overview of the literature on the use of optical (spectacles, contact lenses, and orthokeratology) and pharmaceutical approaches to slow progress of myopia. The evidence indicates that myopia progression can be slowed by varying degrees using these strategies. All...

Possible increase of myopia prevalence among children in Sweden.

The purpose of this study was to determine the prevalence of myopia in a population of children in Sweden. Retrospective analysis of children in a region in Sweden referred to eye care from the national health controls of children. Anonymised patient data of prescription of glasses for myopia was used. During the study period 2008 to 2017, 297 children between 4-7 years was prescribed glasses because of myopia. The incidence for myopia increased from 0,13% to 0,36%. The prevalence of myopia for the same gro...

Choroidal Detachment and Increased Intraocular Pressure in a Case of Secondary Pulmonary Hypertension.

To report a case of secondary pulmonary hypertension, choroidal detachment, and increased intraocular pressure in a patient with a congenital ventricular septal defect.


Advertisement
Quick Search
Advertisement
Advertisement